Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid

Phase 3 Not yet recruiting 200 enrolled Chengdu Kangnuoxing Biopharma,Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Stapokibart in subjects with Moderate to Severe Bullous Pemphigoid.

Timeline

Start: 2025-11-11
Primary completion: 2028-03-27
Completion: 2028-05-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CM310	Monoclonal antibody	—	Subcutaneous

Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid

Summary

Timeline

Drugs

Indications